Selected research
Market Structure
Global Endometriosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Endometriosis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Endometriosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Endometriosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Endometriosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Endometriosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Endometriosis Drugs include Takeda Pharmaceutical Company, Pfizer, AbbVie, AstraZeneca, ValiRx, Roivant Sciences, Repros Therapeutics, ObsEva and Neurocrine Biosciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Endometriosis Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Endometriosis Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Endometriosis Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Endometriosis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Endometriosis Drugs Segment by Company
Takeda Pharmaceutical Company
Pfizer
AbbVie
AstraZeneca
ValiRx
Roivant Sciences
Repros Therapeutics
ObsEva
Neurocrine Biosciences
Kissei Pharmaceutical
Evotec
Debiopharm Group
Astellas Pharma
Endometriosis Drugs Segment by Type
Chinese Herbs
Progestogens
Hormonal Therapy
Add-back Medication
Endometriosis Drugs Segment by Application
Research Institutes
Hospitals
Clinics
Endometriosis Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endometriosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Endometriosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endometriosis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Endometriosis Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Endometriosis Drugs industry.
Chapter 3: Detailed analysis of Endometriosis Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Endometriosis Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chinese Herbs
- Progestogens
- Hormonal Therapy
- Add-back Medication
Applications
- Research Institutes
- Hospitals
- Clinics
Companies covered
- Takeda Pharmaceutical Company
- Pfizer
- AbbVie
- AstraZeneca
- ValiRx
- Roivant Sciences
- Repros Therapeutics
- ObsEva
- Neurocrine Biosciences
- Kissei Pharmaceutical
- Evotec
- Debiopharm Group
- Astellas Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Endometriosis Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Chinese Herbs
- 1.2.3 Progestogens
- 1.2.4 Hormonal Therapy
- 1.2.5 Add-back Medication
- 1.3 Market Analysis by Application
- 1.3.1 Global Endometriosis Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Research Institutes
- 1.3.3 Hospitals
- 1.3.4 Clinics
- 1.4 Global Market Growth Prospects
- 1.5 Global Endometriosis Drugs Growth Trends by Region
- 1.5.1 Global Endometriosis Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Endometriosis Drugs Market Size by Region (2021-2026)
- 1.5.3 Endometriosis Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Endometriosis Drugs Market Dynamics
- 2.1 Endometriosis Drugs Industry Trends
- 2.2 Endometriosis Drugs Industry Drivers
- 2.3 Endometriosis Drugs Industry Opportunities and Challenges
- 2.4 Endometriosis Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Endometriosis Drugs Revenue by Company (2021-2026)
- 3.2 Global Endometriosis Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Endometriosis Drugs Key Company Head office and Area Served
- 3.4 Global Endometriosis Drugs Company, Product Type & Application
- 3.5 Global Endometriosis Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Endometriosis Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Endometriosis Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Endometriosis Drugs Tier 1, Tier 2, and Tier 3
4 Endometriosis Drugs Market by Type
- 4.1 Global Endometriosis Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Endometriosis Drugs Market Size by Type (2021-2032)
- 4.3 Global Endometriosis Drugs Market Size Share by Type (2021-2032)
5 Endometriosis Drugs Market by Application
- 5.1 Global Endometriosis Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Endometriosis Drugs Market Size by Application (2021-2032)
- 5.3 Global Endometriosis Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Takeda Pharmaceutical Company
- 6.1.1 Takeda Pharmaceutical Company Company Information
- 6.1.2 Takeda Pharmaceutical Company Business Overview
- 6.1.3 Takeda Pharmaceutical Company Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Takeda Pharmaceutical Company Endometriosis Drugs Product Portfolio
- 6.1.5 Takeda Pharmaceutical Company Recent Developments
- 6.2 Pfizer
- 6.2.1 Pfizer Company Information
- 6.2.2 Pfizer Business Overview
- 6.2.3 Pfizer Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Pfizer Endometriosis Drugs Product Portfolio
- 6.2.5 Pfizer Recent Developments
- 6.3 AbbVie
- 6.3.1 AbbVie Company Information
- 6.3.2 AbbVie Business Overview
- 6.3.3 AbbVie Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 AbbVie Endometriosis Drugs Product Portfolio
- 6.3.5 AbbVie Recent Developments
- 6.4 AstraZeneca
- 6.4.1 AstraZeneca Company Information
- 6.4.2 AstraZeneca Business Overview
- 6.4.3 AstraZeneca Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 AstraZeneca Endometriosis Drugs Product Portfolio
- 6.4.5 AstraZeneca Recent Developments
- 6.5 ValiRx
- 6.5.1 ValiRx Company Information
- 6.5.2 ValiRx Business Overview
- 6.5.3 ValiRx Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 ValiRx Endometriosis Drugs Product Portfolio
- 6.5.5 ValiRx Recent Developments
- 6.6 Roivant Sciences
- 6.6.1 Roivant Sciences Company Information
- 6.6.2 Roivant Sciences Business Overview
- 6.6.3 Roivant Sciences Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Roivant Sciences Endometriosis Drugs Product Portfolio
- 6.6.5 Roivant Sciences Recent Developments
- 6.7 Repros Therapeutics
- 6.7.1 Repros Therapeutics Company Information
- 6.7.2 Repros Therapeutics Business Overview
- 6.7.3 Repros Therapeutics Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Repros Therapeutics Endometriosis Drugs Product Portfolio
- 6.7.5 Repros Therapeutics Recent Developments
- 6.8 ObsEva
- 6.8.1 ObsEva Company Information
- 6.8.2 ObsEva Business Overview
- 6.8.3 ObsEva Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 ObsEva Endometriosis Drugs Product Portfolio
- 6.8.5 ObsEva Recent Developments
- 6.9 Neurocrine Biosciences
- 6.9.1 Neurocrine Biosciences Company Information
- 6.9.2 Neurocrine Biosciences Business Overview
- 6.9.3 Neurocrine Biosciences Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Neurocrine Biosciences Endometriosis Drugs Product Portfolio
- 6.9.5 Neurocrine Biosciences Recent Developments
- 6.10 Kissei Pharmaceutical
- 6.10.1 Kissei Pharmaceutical Company Information
- 6.10.2 Kissei Pharmaceutical Business Overview
- 6.10.3 Kissei Pharmaceutical Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Kissei Pharmaceutical Endometriosis Drugs Product Portfolio
- 6.10.5 Kissei Pharmaceutical Recent Developments
- 6.11 Evotec
- 6.11.1 Evotec Company Information
- 6.11.2 Evotec Business Overview
- 6.11.3 Evotec Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Evotec Endometriosis Drugs Product Portfolio
- 6.11.5 Evotec Recent Developments
- 6.12 Debiopharm Group
- 6.12.1 Debiopharm Group Company Information
- 6.12.2 Debiopharm Group Business Overview
- 6.12.3 Debiopharm Group Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Debiopharm Group Endometriosis Drugs Product Portfolio
- 6.12.5 Debiopharm Group Recent Developments
- 6.13 Astellas Pharma
- 6.13.1 Astellas Pharma Company Information
- 6.13.2 Astellas Pharma Business Overview
- 6.13.3 Astellas Pharma Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Astellas Pharma Endometriosis Drugs Product Portfolio
- 6.13.5 Astellas Pharma Recent Developments
7 North America
- 7.1 North America Endometriosis Drugs Market Size (2021-2032)
- 7.2 North America Endometriosis Drugs Market Size by Type
- 7.2.1 North America Endometriosis Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Endometriosis Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Endometriosis Drugs Market Share by Type (2021-2032)
- 7.3 North America Endometriosis Drugs Market Size by Application
- 7.3.1 North America Endometriosis Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Endometriosis Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Endometriosis Drugs Market Share by Application (2021-2032)
- 7.4 North America Endometriosis Drugs Market Size by Country
- 7.4.1 North America Endometriosis Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Endometriosis Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Endometriosis Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Endometriosis Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Endometriosis Drugs Market Size (2021-2032)
- 8.2 Europe Endometriosis Drugs Market Size by Type
- 8.2.1 Europe Endometriosis Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Endometriosis Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Endometriosis Drugs Market Share by Type (2021-2032)
- 8.3 Europe Endometriosis Drugs Market Size by Application
- 8.3.1 Europe Endometriosis Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Endometriosis Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Endometriosis Drugs Market Share by Application (2021-2032)
- 8.4 Europe Endometriosis Drugs Market Size by Country
- 8.4.1 Europe Endometriosis Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Endometriosis Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Endometriosis Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Endometriosis Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Endometriosis Drugs Market Size (2021-2032)
- 9.2 China Endometriosis Drugs Market Size by Type
- 9.2.1 China Endometriosis Drugs Market Size by Type (2021-2026)
- 9.2.2 China Endometriosis Drugs Market Size by Type (2027-2032)
- 9.2.3 China Endometriosis Drugs Market Share by Type (2021-2032)
- 9.3 China Endometriosis Drugs Market Size by Application
- 9.3.1 China Endometriosis Drugs Market Size by Application (2021-2026)
- 9.3.2 China Endometriosis Drugs Market Size by Application (2027-2032)
- 9.3.3 China Endometriosis Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Endometriosis Drugs Market Size (2021-2032)
- 10.2 Asia Endometriosis Drugs Market Size by Type
- 10.2.1 Asia Endometriosis Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Endometriosis Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Endometriosis Drugs Market Share by Type (2021-2032)
- 10.3 Asia Endometriosis Drugs Market Size by Application
- 10.3.1 Asia Endometriosis Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Endometriosis Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Endometriosis Drugs Market Share by Application (2021-2032)
- 10.4 Asia Endometriosis Drugs Market Size by Country
- 10.4.1 Asia Endometriosis Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Endometriosis Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Endometriosis Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Endometriosis Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Endometriosis Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Endometriosis Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Endometriosis Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Endometriosis Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Endometriosis Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Endometriosis Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Endometriosis Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Endometriosis Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Endometriosis Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Endometriosis Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Endometriosis Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Endometriosis Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Endometriosis Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Endometriosis Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst